Geron stock
GERNNASDAQGeron Corporation, HealthcareISIN US3741631036
35Score 35 out of 100, Weak
Price and trend
39 / 100
Price history
−20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 29% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 49% below its 52-week high. Largest decline in 20 years: 90% (May 2007 to March 2020).
Chart figures for advanced users
- SMA 50$1.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.89
- The lowest closing price of the last twelve months.
- Resistance$1.95
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Geron Corporation belongs to the Biotechnology industry (United States) and, with a market value of $640.37M, is number 229 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $183.88M (up 138.8% year on year) and a loss of $85.78M.
- For fiscal 2026, analysts expect on average revenue of $235.36M (up 28%) and adjusted earnings per share of −$0.05.
Show more
- MEQIRI Score 35 out of 100 (Weak): rank 636 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 273.5% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $288.37M, financial debt $165.14M.
Weaknesses
- DilutionShare count up 146% since 2020.Capital allocation 18
- Loss-makingLoss of $50.12M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$91.19M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 34 to 35.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.6% on the twelve months before. Revenue has grown strongly since 2006, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating −29%, net −47%. Last 12 months: net −23%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.00 (expected −$0.01)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 5.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.05−5.9%
- Revenue
- $235.36M−0.4%
- Earnings per share
- $0.070.0%
- Revenue
- $341.05M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +17.2%RYTELO net revenue is now expected at the mid to high end of the $220 million to $240 million guidance range; operating expense guidance of $230 million to $240 million unchanged.
“Based on our solid net revenue performance in the first half of the year, we anticipate coming in at the mid- to high end of our full year 2026 RYTELO net product revenue guidance range of $220 million to $240 million. We continue to expect total operating expenses for 2026 in the range of $230 million to $240 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Robertson MichelleSale
18 Feb 2026, EVP, CHIEF FINANCIAL OFFICER
- Shares
- 9,855
- Price
- $1.94
- Value
- $19,119
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Geron
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Aclaris TherapeuticsACRS $688.38M39
- Kura OncologyKURA $687.67M28
- Sana BiotechnologySANA $686.16M30
- Wave Life SciencesWVE $674.52M38
- Capricor TherapeuticsCAPR $649.77M32
- Monopar TherapeuticsMNPR $612.75M42
- GenfitGNFT.PA $609.09M44
- Helus PharmaHELP $582.03M40
ETFs that hold Geron
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.05% | 0.40% | €807M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.